gustavo-frazao-shutterstock-com-patent-

Gustavo Frazao / Shutterstock.com

16 March 2016Americas

PTAB gives green light to four Acorda IPR trials

The Patent Trial and Appeal Board (PTAB) has instituted trials on four patents owned by Acorda Therapeutics following challenges from the Coalition for Affordable Drugs and hedge fund manager Kyle Bass.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Kyle Bass Ampyra IPR challenge is ‘harassment’, says Acorda

16 December 2015 Biotechnology company Acorda Therapeutics has urged the Patent Trial and Appeal Board not to institute an inter partes review petition filed by the Coalition for Affordable Drugs, an organisation linked to hedge fund manager Kyle Bass.

Acorda hits back at Kyle Bass IPR

28 May 2015 Acorda Therapeutics, the first company to be targeted through an inter partes review filed by US hedge fund manager Kyle Bass, has asked the US Patent and Trademark Office to reject the petition.

More on this story

Kyle Bass Ampyra IPR challenge is ‘harassment’, says Acorda

16 December 2015 Biotechnology company Acorda Therapeutics has urged the Patent Trial and Appeal Board not to institute an inter partes review petition filed by the Coalition for Affordable Drugs, an organisation linked to hedge fund manager Kyle Bass.

Acorda hits back at Kyle Bass IPR

28 May 2015 Acorda Therapeutics, the first company to be targeted through an inter partes review filed by US hedge fund manager Kyle Bass, has asked the US Patent and Trademark Office to reject the petition.

More on this story

Kyle Bass Ampyra IPR challenge is ‘harassment’, says Acorda

16 December 2015 Biotechnology company Acorda Therapeutics has urged the Patent Trial and Appeal Board not to institute an inter partes review petition filed by the Coalition for Affordable Drugs, an organisation linked to hedge fund manager Kyle Bass.

Acorda hits back at Kyle Bass IPR

28 May 2015 Acorda Therapeutics, the first company to be targeted through an inter partes review filed by US hedge fund manager Kyle Bass, has asked the US Patent and Trademark Office to reject the petition.

More features

In-house with Bayer: ‘Focus on quality early and stay close to inventors’

Explainer: ARIPO’s role in Plant Variety Protection

J&J sues over schizophrenia drug generic following patent victory

WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’

Powell Gilbert launches Düsseldorf office with leading patent litigator

Startups toolkit: Why investors want more than patents

J&J fends off generic schizophrenia drug bids